Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Multiple sclerosis: Spinal cord grey matter loss correlates with disability in MS.
Birth outcomes of pregnancies fathered by men with multiple sclerosis.
Teva and Takeda announce agreement for glatiramer acetate for multiple sclerosis treatment in Japan
TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis.
In vitro screening of NADPH oxidase inhibitors and in vivo effects of L-leucinethiol on experimental autoimmune encephalomyelitis-induced mice.
Early Growth Response Gene-2 Controls IL-17 Expression and Th17 Differentiation by Negatively Regulating Batf.
On dihydroorotate dehydrogenases, their inhibitors and uses.
Norovirus-related chronic diarrhea in a patient treated with alemtuzumab for chronic lymphocytic leukemia.
Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis.
From "Wheelchair Circuit" to "Wheelchair Assessment Instrument for People with Multiple Sclerosis": Reliability and Validity Analysis of a Test to Assess Driving Skills in Manual Wheelchair Users With Multiple Sclerosis.
Interferon-β and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS.
Brain parenchymal damage in neuromyelitis optica spectrum disorder - A multimodal MRI study.
New Analysis Suggests Aubagio® (teriflunomide) Slows Brain Atrophy in People with Relapsing Multiple Sclerosis
Effect of treatment with interferon beta-1a on changes in voxel-wise magnetization transfer ratio in normal appearing brain tissue and lesions of patients with relapsing-remitting multiple sclerosis: a 24-week, controlled pilot study.
Novartis receives European Commission approval for Gilenya®, the first oral multiple sclerosis treatment for use in the EU
Neuromyelitis optica presenting with relapses under treatment with natalizumab: a case report.
Mesenchymal stem cells as treatment for MS - progress to date.
Placebo? no thanks, it might be bad for me!
Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis.
Protective Associations of HDL with Blood Brain Barrier Injury in Multiple Sclerosis Patients.
Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis.
Severe haematological complications during treatment with natalizumab.
Plasma exchange in severe attacks of neuromyelitis optica.
Endogenous retroviruses and multiple sclerosis--new pieces to the puzzle.
Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.

Pages